| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 114-123, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
DW Hsu, JT Efird and ET Hedley-Whyte
Division of Neuropathology, Massachusetts General Hospital 02114, USA.
Urokinase-type plasminogen activator (u-PA) is a 54-kd enzyme shown to participate in tissue degradation under certain normal and pathological conditions, including cancer invasion and metastasis. Increased u-PA expression has been found in cancers of the breast, lung, colon, and prostate, and correlated with worse outcome in patients with lung and breast cancer. We examined the correlation between u-PA expression in gliomas and patient survival. Seventy-seven gliomas from 41 men and 36 women (ages 2 to 73) were immunostained for u-PA using monoclonal antibody 394 directed against human urokinase. The tumors included 32 grade 4, 16 grade 3, and 20 grade 2 astrocytomas (Daumas-Duport scale), and 9 pilocytic astrocytomas. Strong cytoplasmic staining was found in tumor cells of all grade 4, most of the grade 3, and a few of the lower grade tumors. Adjacent normal brain tissue showed faint staining associated with subpial cell processes and white matter fibers. The fiber staining was stronger in brain tissue infiltrated by tumor cells. Cytoplasmic u-PA staining in tumor cells was scored from 0 (no staining) to 6 (strong and widespread staining). The mean u-PA scores were 5.08 +/- 0.19 (mean +/- SEM) for grade 4, 3.97 +/- 0.46 for grade 3, 1.65 +/- 0.39 for grade 2, and 1.22 +/- 0.60 for pilocytic astrocytomas. The statistical analysis was based on cytoplasmic staining only. Analysis of variance revealed significant differences between the mean u-PA scores of different grades (P < 0.02 between grades 4 and 3, and P = 0.0001 between grades 4 or 3 and 2, and between grades 4 or 3 and pilocytic), except between grade 2 and pilocytic astrocytomas. Univariate analysis indicated that u-PA score > or = 4 (P = 0.0001), tumor grade 4 (P = 0.01), and age > 50 (P < 0.001) were all significant predictors for shorter disease survival. A three-way interaction model by multivariate analysis indicated that u-PA score > or = 4, tumor grade 4, and age > 50, taken together, were significant factors for shorter patient survival (P < 0.02). We conclude that u-PA may be used as a prognostic tool in conjunction with tumor grade and patients' age in predicting survival for patients with gliomas.
This article has been cited by other articles:
 |
|
 |
|
  S. M. K. Pulukuri, B. Gorantla, and J. S. Rao Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. K. Pulukuri and J. S. Rao Small Interfering RNA Directed Reversal of Urokinase Plasminogen Activator Demethylation Inhibits Prostate Tumor Growth and Metastasis Cancer Res., July 15, 2007; 67(14): 6637 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ortiz-Zapater, S. Peiro, O. Roda, J. M. Corominas, S. Aguilar, C. Ampurdanes, F. X. Real, and P. Navarro Tissue Plasminogen Activator Induces Pancreatic Cancer Cell Proliferation by a Non-Catalytic Mechanism That Requires Extracellular Signal-Regulated Kinase 1/2 Activation through Epidermal Growth Factor Receptor and Annexin A2 Am. J. Pathol., May 1, 2007; 170(5): 1573 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. K. Pulukuri, N. Estes, J. Patel, and J. S. Rao Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer Cancer Res., February 1, 2007; 67(3): 930 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reijneveld, D. Brandsma, W. Boogerd, J.G.M. Bonfrer, S. Kalmijn, E. E. Voest, A. Geurts-Moespot, M. C. Visser, and M. J.B. Taphoorn CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases Neurology, October 11, 2005; 65(7): 1120 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Bauer, W. Liu, F. Fan, E. R. Camp, A. Yang, R. J. Somcio, C. D. Bucana, J. Callahan, G. C. Parry, D. B. Evans, et al. Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice Cancer Res., September 1, 2005; 65(17): 7775 - 7781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pakneshan, B. Tetu, and S. A. Rabbani Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma Clin. Cancer Res., May 1, 2004; 10(9): 3035 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mohanam, S. L. Jasti, S. R. Kondraganti, N. Chandrasekar, Y. Kin, G. N. Fuller, S. S. Lakka, A. P. Kyritsis, D. H. Dinh, W. C. Olivero, et al. Stable Transfection of Urokinase-Type Plasminogen Activator Antisense Construct Modulates Invasion of Human Glioblastoma Cells Clin. Cancer Res., August 1, 2001; 7(8): 2519 - 2526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Helenius, O. R. Saramaki, M. J. Linja, T. L. J. Tammela, and T. Visakorpi Amplification of Urokinase Gene in Prostate Cancer Cancer Res., July 1, 2001; 61(14): 5340 - 5344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Strojnik, J. Kos, B. Zidanik, R. Golouh, and T. Lah Cathepsin B Immunohistochemical Staining in Tumor and Endothelial Cells Is a New Prognostic Factor for Survival in Patients with Brain Tumors Clin. Cancer Res., March 1, 1999; 5(3): 559 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ferrier, W. L. van Geloof, H. H. de Witte, M. D. Kramer, D. J. Ruiter, and G. N.P. van Muijen Epitopes of Components of the Plasminogen Activation System are Re-exposed in Formalin-fixed Paraffin Sections by Different Retrieval Techniques J. Histochem. Cytochem., April 1, 1998; 46(4): 469 - 476. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
